TABLE 3 

Relative changes in BCRP mRNA expression in pancreatic cancer cell lines after treatment with anticancer drugs compared with control (no treatment)

Analysis of mRNA expression was performed after a 72-hour incubation with each anticancer drug. BCRP mRNA expression levels were normalized to those of β-actin. Data represent the mean ± S.D. (n = 3).

DrugPANC-1AsPC-1HPAF-IISW 1990MIA PaCa-2
ConcentrationMean ± S.D.ConcentrationMean ± S.D.ConcentrationMean ± S.D.ConcentrationMean ± S.D.ConcentrationMean ± S.D.
µMµMµMµMµM
Control1.0 ± 0.0561.0 ± 0.0321.0 ± 0.121.0 ± 0.131.0 ± 0.19
SN-380.31.8 ± 0.180.11.4 ± 0.340.10.76 ± 0.0530.011.3 ± 0.170.018.3 ± 1.4
11.8 ± 0.280.30.94 ± 0.150.31.2 ± 0.250.031.0 ± 0.0960.0315 ± 1.7
Topotecan11.7 ± 0.240.31.5 ± 0.0700.30.76 ± 0.0440.031.4 ± 0.110.033.1 ± 0.19
31.8 ± 0.1810.75 ± 0.09710.83 ± 0.0800.10.85 ± 0.140.117 ± 0.89
Mitoxantrone0.12.0 ± 0.150.31.3 ± 0.200.30.65 ± 0.0900.10.70 ± 0.140.0317 ± 1.8
0.31.8 ± 0.1410.75 ± 0.08911.2 ± 0.200.31.1 ± 0.140.120 ± 1.4
Dinaciclib0.010.73 ± 0.0180.010.98 ± 0.170.0030.78 ± 0.0400.0030.76 ± 0.0550.0031.2 ± 0.17
0.031.9 ± 0.130.030.99 ± 0.0870.011.2 ± 0.0570.011.3 ± 0.190.014.1 ± 0.45
Flavopiridol0.10.65 ± 0.0940.10.97 ± 0.100.11.2 ± 0.110.030.71 ± 0.100.030.99 ± 0.085
0.31.2 ± 0.170.31.7 ± 0.310.31.5 ± 0.130.10.76 ± 0.120.11.7 ± 0.25